Osteal Therapeutics Funding Round

9/25/2023

Venture Equity

$23,000,000

Series C

The company intends to use the funds to submit its New Drug Application (NDA) submission to FDA and accelerate preparation for commercial launch of VT-X7, its lead therapy for the treatment of periprosthetic joint infection (PJI).

Private & Independent

Biopharmaceutical

PO BOX 140740 520
Dallas, TX 75214
USA

Undisclosed

Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences. The lead product under development, VT-X7, is a drug-device combination product that has the potential to be the first FDA approved antibiotic therapy for local delivery to treat infected joint prosthesis. If approved, VT-X7 has the potential to improve outcomes and lower the cost of care for orthopedic surgeons and their patients by providing a faster, more reliable treatment option. VT-X7 has undergone extensive pre-clinical development and successfully completed a Phase 2 clinical trial in late 2020.